Compare ADT Inc (ADT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Novartis AG — how do they compare? ADT Inc trades at $7.39 (market cap $5.58B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 53.4× ADT Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| ADT | NVS | |
|---|---|---|
Market Cap | $5.58B | $298.18B |
Sector | Industrials | Health |
52-Week High | $8.85 | $168.62 |
52-Week Low | $6.30 | $119.31 |
Enterprise Value | $13.27B | $339.50B |
Dividend Yield | 2.88% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.64, down 0.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.23, beating estimates, and maintains strong profitability with an 11.86% net margin. Recent news highlights ADT's sponsorship of National Night Out 2026 and recognition as a top home security brand by Newsweek in May 2026.
Outlook is positive with consistent earnings beats and a 47% analyst buy rating, but risks include high debt levels and competitive pressures. The stock offers value with a P/E of 10.61 and dividend yield near 1.6%, supported by AI-driven growth initiatives.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
